Kostas Tepelenis

Dr. Kostas Tepelenis


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2021 in In Vivo
Verified
Journal Article
Closed access
PDF file
KTKostas Tepelenis
Kostas Tepelenis
GPGeorgios Papathanakos
Georgios Papathanakos
AKAikaterini Kitsouli
Aikaterini Kitsouli
TTTheodoros Troupis
Theodoros Troupis
ABAlexandra Barbouti
Alexandra Barbouti
PKPanagiotis Kitsoulis
Panagiotis Kitsoulis
Osteochondroma, the most common benign bone tumor, is a projection on the external surface of the bone, which can be sessile or pedunculated. 85% of osteochondromas present as solitary lesions, while 15% occur in the context of hereditary multiple exostoses (HME), a genetic disorder that is inherited in an autosomal dominant manner. Although often asymptomatic, symptoms may eventuate from compression of adjacent vessels or nerves, fractures, osseous deformities, bursa formation, or malignant transformation. Cartilage cap thickness >2 cm in adults or >3 cm in children as well as new onset of pain or growth, or rapid growth of the lesion, especially after the closure of the growth plate, might reflect cancerous transformation. Surgical resection is indicated for symptomatic lesions, complications, cosmetic reasons or malignant transformation. Excision of the tumor with free margin is the treatment of choice. Local recurrence is less than 2% if complete resection is achieved.

21 June 2021 in In Vivo
Verified
Journal Article
Closed access
PDF file
KTKostas Tepelenis
Kostas Tepelenis
GSGeorgios P. Skandalakis
Georgios P. Skandalakis
GPGeorgios Papathanakos
Georgios Papathanakos
MKMaria Alexandra Kefala
Maria Alexandra Kefala
AKAikaterini Kitsouli
Aikaterini Kitsouli
PKPanagiotis Kitsoulis
Panagiotis Kitsoulis
Osteoid osteoma, the third most common benign bone tumor, usually occurs in the cortex of long bones. It consists of a radiolucent nidus surrounded by reactive osteosclerosis. Generally, osteoid osteoma affects young males. Nocturnal pain that eases with salicylates or nonsteroidal anti-inflammatory drugs (NSAID) is the typical clinical presentation. Sometimes, it remains undiagnosed for a long time. Plain radiography and computed tomography are usually sufficient for the diagnosis of osteoid osteoma. Initial treatment includes salicylates and NSAID because the tumor often regresses spontaneously over 2-6 years. Surgical treatment is indicated in case of unresponsive pain to medical therapy, no tolerance of prolonged NSAID therapy due to side effects, and no willingness to activity limitations. Nowadays, minimally invasive techniques have replaced open surgery and are considered the gold standard of surgical treatment. Although cryoablation seems superior in terms of the nerve damage and immunotherapy effect, radiofrequency ablation is the preferred technique.

15 September 2022 in World Journal of Surgery
Verified
Journal Article
Open access
PDF file
Konstantinos LasithiotakisKonstantinos Lasithiotakis
Konstantinos Lasithiotakis
Evangelos I. KritsotakisEvangelos I. Kritsotakis
Evangelos I. Kritsotakis
SKStamatios Kokkinakis
Stamatios Kokkinakis
GPGeorgia Petra
Georgia Petra
KPKonstantinos Paterakis
Konstantinos Paterakis
ECEmmanuel Chrysos
Emmanuel Chrysos
Background: Emergency laparotomy (EL) is accompanied by high post‐operative morbidity and mortality which varies significantly between countries and populations. The aim of this study is to report outcomes of emergency laparotomy in Greece and to compare them with the results of the National Emergency Laparotomy Audit (NELA).Methods: This is a multicentre prospective cohort study undertaken between 01.2019 and 05.2020 including consecutive patients subjected to EL in 11 Greek hospitals. EL was defined according to NELA criteria. Demographics, clinical variables, and post‐operative outcomes were prospectively registered in an online database. Multivariable logistic regression analysis was used to identify independent predictors of post‐operative mortality.Results: There were 633 patients, 53.9% males, ASA class III/IV 43.6%, older than 65 years 58.6%. The most common operations were small bowel resection (20.5%), peptic ulcer repair (12.0%), adhesiolysis (11.8%) and Hartmann's procedure (11.5%). 30‐day post‐operative mortality reached 16.3% and serious complications occurred in 10.9%. Factors associated with post‐operative mortality were increasing age and ASA class, dependent functional status, ascites, severe sepsis, septic shock, and diabetes. HELAS cohort showed similarities with NELA patients in terms of demographics and preoperative risk. Post‐operative utilisation of ICU was significantly lower in the Greek cohort (25.8% vs 56.8%) whereas 30‐day post‐operative mortality was significantly higher (16.3% vs 8.7%).Conclusion: In this study, Greek patients experienced markedly worse mortality after emergency laparotomy compared with their British counterparts. This can be at least partly explained by underutilisation of critical care by surgical patients who are at high risk for death.

18 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
GPGeorgios Pappas-Gogos
Georgios Pappas-Gogos
KTKostas Tepelenis
Kostas Tepelenis
FFFotios S. Fousekis
Fotios S. Fousekis
KKKonstantinos H. Katsanos
Konstantinos H. Katsanos
MPMichail Pitiakoudis
Michail Pitiakoudis
KVKonstantinos Vlachos
Konstantinos Vlachos
Gastric cancer (GC) is one of the most common and deadly malignancies worldwide. Helicobacter pylori have been documented as a risk factor for GC. The development of sequencing technology has broadened the knowledge of the gastric microbiome, which is essential in maintaining homeostasis. Recent studies have demonstrated the involvement of the gastric microbiome in the development of GC. Therefore, the elucidation of the mechanism by which the gastric microbiome contributes to the development and progression of GC may improve GC’s prevention, diagnosis, and treatment. In this review, we discuss the current knowledge about changes in gastric microbial composition in GC patients, their role in carcinogenesis, the possible therapeutic role of the gastric microbiome, and its implications for current GC therapy.

23 April 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FFFotios S. Fousekis
Fotios S. Fousekis
IMIoannis V. Mitselos
Ioannis V. Mitselos
KTKostas Tepelenis
Kostas Tepelenis
GPGeorgios Pappas-Gogos
Georgios Pappas-Gogos
KKKonstantinos H. Katsanos
Konstantinos H. Katsanos
DCDimitrios K Christodoulou
Dimitrios K Christodoulou
The development of fibrostenotic intestinal disease occurs in approximately one-third of patients with Crohn’s disease and is associated with increased morbidity. Despite introducing new biologic agents, stricturing Crohn’s disease remains a significant clinical challenge. Medical treatment is considered the first-line treatment for inflammatory strictures, and anti-TNF agents appear to provide the most considerable benefit among the available medical treatments. However, medical therapy is ineffective on strictures with a mainly fibrotic component, and a high proportion of patients under anti-TNF will require surgery. In fibrotic strictures or cases refractory to medical treatment, an endoscopic or surgical approach should be considered depending on the location, length, and severity of the stricture. Both endoscopic balloon dilatation and endoscopic stricturoplasty are minimally invasive and safe, associated with a small risk of complications. On the other hand, the surgical approach is indicated in patients not suitable for endoscopic therapy. This review aimed to present and analyze the currently available medical, endoscopic, and surgical management of stricturing Crohn’s disease.

25 April 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
KTKostas Tepelenis
Kostas Tepelenis
GPGeorgios Pappas-Gogos
Georgios Pappas-Gogos
PNPanagiotis Ntellas
Panagiotis Ntellas
KTKonstantinos Tsimogiannis
Konstantinos Tsimogiannis
KDKaterina Dadouli
Katerina Dadouli
GGGeorgios K. Glantzounis
Georgios K. Glantzounis
Background: The indications of preoperative chemotherapy, for initially resectable synchronous colorectal liver metastases, remain controversial. This meta-analysis aimed to assess the efficacy and safety of preoperative chemotherapy in such patients. Methods: Six retrospective studies were included in the meta-analysis with 1036 patients. Some 554 patients were allocated to the preoperative group, and 482 others were allocated to the surgery group. Results: Major hepatectomy was more common in the preoperative group than in the surgery group (43.1% vs. 28.8%, p < 0.001). Furthermore, the percentage of patients with more than three liver metastases was higher in the preoperative group compared to the surgery group (12.6% vs. 5.4%, p < 0.002). Preoperative chemotherapy showed no statistically significant impact on overall survival. Combined disease free/relapse survival analysis of patients with high disease burden (liver metastases > 3, maximum diameter > 5 cm, clinical risk score ≥ 3) demonstrated that there is a 12% lower risk of recurrence in favor of preoperative chemotherapy. Combined analysis showed a statistically significant (77% higher probability) of postoperative morbidity in patients who received preoperative chemotherapy (p = 0.002). Conclusions: Preoperative chemotherapy should be suggested in patients with high disease burden. The number of cycles of preoperative chemotherapy should be low (3–4) to avoid increased postoperative morbidity. However more prospective studies are needed to clarify the exact role of preoperative chemotherapy in patients with synchronous resectable colorectal liver metastases.